Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Opaganib - RedHill Biopharma

Drug Profile

Opaganib - RedHill Biopharma

Alternative Names: ABC 294640; YELIVA

Latest Information Update: 21 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Apogee Biotechnology Corporation
  • Developer Apogee Biotechnology Corporation; Medical University of South Carolina; RedHill Biopharma
  • Class Adamantanes; Anti-inflammatories; Antineoplastics; Antirheumatics; Pyridines; Small molecules
  • Mechanism of Action Sphingosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cholangiocarcinoma
  • New Molecular Entity Yes
  • Available For Licensing Yes - Cancer; Inflammation

Highest Development Phases

  • Phase II Cholangiocarcinoma; Liver cancer
  • Phase I/II Multiple myeloma
  • Phase I Solid tumours
  • Clinical Phase Unknown Cancer
  • Preclinical Prostate cancer
  • No development reported Inflammatory bowel diseases; Osteoarthritis; Radiation injuries; Rheumatoid arthritis

Most Recent Events

  • 14 Nov 2018 Efficacy and adverse events data from a phase Ib/II trial in Multiple myeloma and pharmacodynamics data from preclinical studies in Cancer released by RedHill Biopharma
  • 24 Jun 2018 Biomarkers information updated
  • 30 Jan 2018 RedHill Biopharma initiates an expanded-access programme for Cholangiocarcinoma in Germany(NCT03414489)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top